rescue cell infusion
Graft-versus-host-disease (GvHD) is the major complication of allogeneic hematopoietic stem cell transplantation (HSCT). No treatment is effective for patients with progressive GvHD refractory to steroids and lymphocytotoxic agents.
1-2 Some patients may have autologous backup stem cells stored from prior autologous stem cell harvest. These cells have been used previously to treat graft failure. 3 Such autologous 'rescue' cell transfusions could potentially be used to treat GvHD. This could result in improvement of GvHD while maintaining donor chimerism, or through reverting hematopoiesis to recipient-type chimerism. Achieving the former could lead to the hypothesis that infusion of regulatory cells was responsible for improved GvHD while achieving the latter could be explained by rejection of the allogeneic graft by autologous cells. Increased relapse risk could be acceptable as severe refractory GvHD is often fatal and surviving patients with GvHD have a very poor quality of life.
Patients with severe refractory GvHD are in a poor state of health and do not tolerate standard myeloablative conditioning regimens. Conversely, transplantation using a low-intensity conditioning regimen successfully inducing a graft-versus-tumor effect, even in patients with poor performance status, has become established and may be tolerated in patients with refractory GvHD. 4 We present data on eight patients treated by three groups of investigators. The patients received autologous or syngeneic 'rescue' transplants with the aim of improving severe refractory GvHD.
Patients and methods
Eight patients, four female, median age 32 (20-45) years, underwent allogeneic stem cell transplantation from HLAidentical siblings (n ¼ 5), unrelated donors (n ¼ 2) or mismatched siblings (n ¼ 1) to treat CML (n ¼ 3), AML (n ¼ 2), ALL (n ¼ 2), or NHL (n ¼ 1). Three patients had early stage disease (CML in chronic phase, AML in CR1), and five had more advanced disease (Table 1 ). All patients developed acute grade III-IV GvHD or extensive chronic GvHD and were refractory to a median of four (range 3-6) lines of GvHD-specific treatment.
Patients received a 'rescue' transplant using autologous (n ¼ 6) cells or cells from a syngeneic donor (n ¼ 2). Recipients of syngeneic 'rescue' transplants had previously undergone an HLA-identical sibling transplant with the goal of inducing a GvL effect, that is, these patients had syngeneic and allogeneic donors available. The median interval between the allogeneic transplant resulting in GvHD and the 'rescue' transplant was 64 (41-270) days. Stem cell source was bone marrow in two and peripheral blood in six. The median stem cell dose was 5.2 (3.6-10.2) Â 10 6 CD34 þ cells/kg or adequate total nucleated cell counts, respectively. Three patients received no conditioning regimen prior to reinfusing 'rescue' cells. Five patients received conditioning of varying intensity, two had reduced intensity regimens and three had an intermediate intensity regimen. Immunosuppressive drugs were maintained after 'rescue' cell infusions in all patients. Transplant details are shown in Table 2 .
Results
'Rescue' cell infusion resulted in resolution of GvHD manifestations in four of eight patients ( Table 2 , patients, 3, 4, 7, and 8), three of whom may have benefited long term from the procedure. Patient 8 is alive, and in remission of CML, patient 7 died 5 years after the 'rescue' cell infusion of CML blast crisis. Both had received an intermediate intensity conditioning regimen and had reverted to recipient-type chimerism. Patient 8 experienced transient chronic gut GvHD post 'rescue' cell infusion, requiring steroids. This was proven by biopsy, and appeared at a time when no donor alleles were detected by chimerism analysis in blood and marrow. Patient 3 received 'rescue' cell infusion without prior conditioning and remained a donor chimera. He nevertheless experienced complete resolution of acute GvHD but developed chronic GvHD 7 months later. He died 2 years after the autologous 'rescue' cell infusion of ALL relapse. The fourth patient, patient 4, had resolution of GvHD but died of multiorgan failure possibly associated with the toxicity of busulfan conditioning. The observation time in this patient was too short to assess whether the response was durable. Chimerism analysis was not done. A fifth patient, patient 6, had transient resolution of GvHD. This patient remained a complete donor chimera after 'rescue' cell infusion, administered without prior conditioning. GvHD recurred when corticosteroids were tapered and ultimately proved fatal. Three patients had no response to the 'rescue' procedure. Patients 1 and 2 had received reduced-intensity conditioning and had reverted to recipient-type or mixed chimerism but with only very minor and transient improvement of GvHD, possibly associated with a fludarabine infusion. In patient 1, who had bronchiolitis obliterans, chimerism analysis on day þ 30 of the syngeneic 'rescue' transplant revealed persistent allogeneic donor cells of 15% in a broncho-alveolar lavage sample at a time when no allogeneic donor alleles could be found in blood or marrow. Patient 5 had received an autologous 'rescue' cell infusion without conditioning and died of fungal infection without GvHD resolution.
Results of chimerism analyses were available in seven patients. Donor chimerism was maintained in the three patients who received stem cell 'rescue' without conditioning, whereas recipient-type or mixed chimerism was achieved in four patients receiving conditioning prior to 'rescue' cell infusion. 
Discussion
GvHD refractory to corticosteroids after allogeneic HSCT is often lethal and numerous experimental strategies have been studied. [5] [6] [7] [8] Martin et al 9 reviewed results of secondline therapies in 427 patients. Improvement was seen in 45% of patients with cutaneous GvHD, in 25% of those with liver GvHD and 35% with gastrointestinal GvHD. Best response was seen in patients in whom GvHD had recurred as corticosteroids were being withdrawn. If this subgroup is excluded, then response to a variety of secondline treatments was shown to be considerably worse. A 'rescue' cell infusion using autologous stem cells could re-establish host hematopoiesis and may exert a graftversus-graft effect 'rejecting' GvHD in ways similar to graft-versus-host and graft-versus-tumor effects. Depletion of donor T cells by the conditioning regimen may also contribute, as may modulation of antigen presentation. Patients with stable mixed chimerism are reported to have low GvHD risks. In patients not losing their chimeric status, mechanisms could include the introduction of host regulatory or veto cells that mitigate GvHD. 7, 10 Such 'rescue' cell infusions may be carried out with or without further pretransplant conditioning. Successful use of DLI and low-intensity conditioning HSCT have demonstrated feasibility of cellular intervention. 4 Patients with refractory GvHD are too sick to undergo standard myeloablative conditioning but may tolerate reduced-intensity regimens. If this strategy proves successful, autologous back-up cells could be harvested in patients considered to be at risk of severe GvHD. Even if this strategy were to result in a high relapse rate, protecting patients from otherwise fatal GvHD may be a worthwhile goal.
Other strategies in pursuit of the same goal include a pseudoautologous graft 11 using mobilized stem cells from the chimeric patient, a 'rescue' transplant with a T-cell depleted graft from the allogeneic donor, or the use of highdose cyclophosphamide alone. Contrary to autologous 'rescue' stem cell transplantation, the latter approaches avoid giving back cells with possible tumor contamination.
We collected data on eight patients who received autologous or syngeneic 'rescue' stem cell infusions to treat severe refractory GvHD. These data show that GvHD resolved in four of eight patients, while four patients died of progressive GvHD. Of the four patients with resolution of GvHD, three survived for a prolonged period without recurrence of severe GvHD, while the fourth patient died shortly after 'rescue' cell infusion of toxicity and could have had GvHD recurrence had she survived longer. GvHD resolved in three of five patients who received a conditioning regimen prior to 'rescue' cell infusion and in of 3 who did not. Donor-type chimerism was maintained in all three patients who did not receive pretransplant conditioning, but reverted to recipient-type or mixed chimerism in four of four evaluated patients receiving conditioning prior to 'rescue' transplantation.
In patient 1, GvHD manifestations were atypical as skin, gut and liver manifestations were not prominent, whereas bronchiolitis obliterans proved life-threatening. The cause of the biopsy-positive demyelinating polyneuropathy was not positively established in this case, but as its course ran in parallel with GvHD progression, it was ascribed to GvHD. 12 In this patient, the 'rescue' transplantation strategy was successful insofar as donor hematopoiesis was replaced by syngeneic/autologous hematopoiesis. GvHD nevertheless persisted and progressed in the lung and chimerism studies of a broncho-alvelolar lavage sample showed persistence of allogeneic alleles at the affected site. This is paralleled in patient 8 who experienced transient chronic steroid responsive GvHD of the gut after 'rescue' transplantation at a time when no donor alleles were detected in the blood. Chimerism analysis of the gut biopsy is not available in this patient. The persistence of allogeneic donor cells at a time when no evidence of donor cells was detected in blood and marrow may mean that GvHDinducing cells persist in affected tissue 13, 14 after elimination from blood or marrow.
Autologous/syngeneic 'rescue' cell infusion may resolve refractory GvHD in some patients. Animal models should continue to evaluate whether established grafts can be rejected by autologous cells. 15 We think that the strategy of autologous 'rescue' cell infusions to treat severe refractory GvHD should be explored further in a larger multiinstitutional phase II study. Data presented here suggest that some form of conditioning is required to reverse donor-type chimerism. The optimal timing, criteria for patient selection, and the best approach to conditioning remain to be defined.
